No CrossRef data available.
Article contents
Making Headway—New Treatments in Parkinson's Disease
Published online by Cambridge University Press: 07 November 2014
Abstract
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
![Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'](https://static.cambridge.org/content/id/urn%3Acambridge.org%3Aid%3Aarticle%3AS1092852900005496/resource/name/firstPage-S1092852900005496a.jpg)
- Type
- Introduction
- Information
- CNS Spectrums , Volume 3 , Issue 2: Pathophysiologic and Clinical Progress in Parkinson's Disease , February 1998 , pp. 22
- Copyright
- Copyright © Cambridge University Press 1998
References
REFERENCES
1.Shannon, KM, Bennett, JP Jr, Friedman, JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Neurology. 1997;49:724–728.CrossRefGoogle ScholarPubMed
2.Lieberman, A, Ranhosky, A, Korts, D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology. 1997;49:162–168.Google Scholar
3.Adler, CH, Sethi, KD, Hauser, RA, et al.Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology. 1997;49:393–399.Google Scholar
4.Rascol, O, Lees, AJ, Senard, JM, Pirtosek, Z, Montastrue, JL, Fuell, D. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol. 1996;19:234–245.Google Scholar